US prevalence
~35% of US adults
Source: NHANES 2017-2018
Affiliate-supportedIndependent editorialWe never sell medicationSee how
A cluster of conditions — abdominal obesity, hypertension, dyslipidemia, impaired fasting glucose — that raise T2D and CVD risk. No GLP-1 is FDA-approved for the syndrome itself. No GLP-1 is FDA-approved for metabolic syndrome as a discrete diagnosis. Coverage and treatment typically flow through component diagnoses (obesity, T2D, CVD risk). Evidence grade: B (consistent benefit across component endpoints). GLP-1 therapy reliably improves all five NCEP-ATP III metabolic syndrome criteria: waist circumference, triglycerides, HDL, blood pressure, and fasting glucose. STEP 1 secondary analyses showed roughly 50% of subjects met metabolic syndrome criteria at baseline and a substantial fraction resolved on treatment.
Metabolic syndrome is a cluster of conditions (central obesity, hypertension, insulin resistance, dyslipidemia) that together increase cardiovascular and diabetes risk. Approximately 35% of US adults have metabolic syndrome. GLP-1 medications address multiple components simultaneously — weight loss, improved insulin sensitivity, reduced blood pressure, improved lipids — making them well-suited for metabolic-syndrome patients with obesity or T2D.
US prevalence
~35% of US adults
Source: NHANES 2017-2018
Last clinical review
By GLP1Zoom editorial board
GLP-1 role
Not specifically FDA-approved for metabolic syndrome but addresses multiple components simultaneously. Often appropriate when patient has obesity or T2D as primary indication.
No GLP-1 is FDA-approved for metabolic syndrome as a discrete diagnosis. Coverage and treatment typically flow through component diagnoses (obesity, T2D, CVD risk). Evidence grade: B (consistent benefit across component endpoints). GLP-1 therapy reliably improves all five NCEP-ATP III metabolic syndrome criteria: waist circumference, triglycerides, HDL, blood pressure, and fasting glucose. STEP 1 secondary analyses showed roughly 50% of subjects met metabolic syndrome criteria at baseline and a substantial fraction resolved on treatment.
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizEndocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly for Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)
Diagnostic algorithm
Who diagnoses: Primary care provider, endocrinologist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
Central adiposity measurement
Threshold: >40 inches (men) or >35 inches (women)
Fasting plasma glucose blood draw
Threshold: ≥100 mg/dL (impaired fasting glucose)
HDL + triglycerides
Threshold: HDL <40 mg/dL (men) or <50 (women); TG ≥150 mg/dL
Multiple measurements
Threshold: ≥130/85 mmHg
NCEP ATP III + 2009 harmonized criteria: 3 of 5 components present
Threshold: ~35% of US adults meet criteria
Source: NCEP ATP III + AHA/NHLBI 2009 Harmonized Criteria
Treatment decision criteria
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Wegovy semaglutide | $1349–$1500/mo | 85/100 | Strong on-label option if BMI ≥27 with weight-related comorbidity | Compare |
| Zepbound tirzepatide | $349–$1086/mo | 85/100 | Strong on-label option if BMI ≥27 with weight-related comorbidity | Compare |
| Ozempic semaglutide | $968–$1100/mo | 78/100 | On-label for type 2 diabetes component of metabolic syndrome | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 78/100 | On-label for type 2 diabetes — strongest metabolic profile improvement | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.